HRTX News and Press, Heron Therapeutics Inc. From 07/21/21

Heron Therapeutics (HRTX) posts new analysis evaluating the efficacy and safety of ZYNRELEF extended-release solution in adults aged 65 years and older undergoing bunionectomy and hernia repair from the Phase 3 EPOCH 1 and EPOCH 2 studies.The analysis showed that 58% of bunionectomy and 87% o...

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™ PR Newswire SAN DIEGO , July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-st...

Heron Therapeutics Inc. (NASDAQ:HRTX) traded at a new 52-week low today of $12.83. This new low was reached on below average trading volume as 223,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Heron Therapeutics Inc. has overhead space with...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap growth stocks regained comparative performance ...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™ PR Newswire SAN DIEGO , July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the live...

Heron Therapeutics (HRTX) announces that ZYNRELEF (bupivacaine and meloxicam) extended-release solution, is now commercially available at all national wholesalers and the largest specialty distributors in the United States.Shares up more than 7% premarket.ZYNRELEF was approved ...

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours - ZYNRELEF, the first and only extended-release local anesthetic, is now available in distribution channels - - Heron has depl...

Among all of the overwhelming and depressing statistics associated with the coronavirus pandemic, here's one number that has sometimes been overlooked: 81,003 people in the U.S. died from drug overdoses in the 12-month period that ended in June 2020. That was a 20% year-over-year increase t...

Heron Therapeutics (HRTX) has filed for an offering of up to 12.4M shares of common stock from a shareholder.The maximum aggregate offering price is $172.3M.Heron shares are down 1.9% to $13.02 in after-hours trading. For further details see: Heron Therapeutics files for 12.4M...